Literature DB >> 25081365

C-reactive protein induces expression of tissue factor and plasminogen activator inhibitor-1 and promotes fibrin accumulation in vein grafts.

Y Ji1, P M Fish, T L Strawn, A W Lohman, J Wu, A J Szalai, W P Fay.   

Abstract

BACKGROUND: C-reactive protein (CRP) promotes tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) expression in vitro, and an elevated plasma CRP concentration is associated with an increased risk of vein graft (VG) thrombosis after coronary artery bypass surgery. However, little is known about the effects of CRP on VG TF and PAI-1 expression in vivo, or on VG thrombosis.
OBJECTIVES: We studied transgenic (Tg) mice expressing human CRP in a VG model to explore in vivo cause-and-effect relationships between CRP and TF, PAI-1, and VG thrombosis.
METHODS: Vein segments from wild-type (WT) and CRP-Tg donors were transplanted into carotid arteries of WT and CRP-Tg recipients. VGs were analyzed 1-4 weeks later.
RESULTS: Human CRP accumulated in VGs during the first 4 weeks after surgery, but appeared to originate exclusively from systemic sources, rather than local production. Human CRP significantly increased TF gene expression, protein concentration and activity in VGs. Human CRP also increased PAI-1 concentrations in VGs, although only in vascular endothelial cells. Human CRP stimulated macrophage migration, invasion into VGs, and TF expression. Fibrin deposition was significantly greater in VGs of CRP-Tg mice than in WT controls.
CONCLUSIONS: CRP accumulates in VGs early after surgery, originating from systemic sources rather than local synthesis. Human CRP promotes TF and PAI-1 expression in VGs, although with different expression patterns. Human CRP stimulates macrophage invasion and fibrin deposition within VGs. These results suggest that CRP induces pathologic changes in VGs that contribute to early VG occlusion.
© 2014 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  C-reactive protein; plasminogen activator inhibitor 1; thrombosis; tissue factor; vascular graft occlusion

Mesh:

Substances:

Year:  2014        PMID: 25081365      PMCID: PMC4194135          DOI: 10.1111/jth.12680

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  36 in total

1.  C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation.

Authors:  Plinio Cirillo; Paolo Golino; Paolo Calabrò; Gaetano Calì; Massimo Ragni; Salvatore De Rosa; Giovanni Cimmino; Mario Pacileo; Raffaele De Palma; Lavinia Forte; Annarita Gargiulo; Fabio Granato Corigliano; Valeria Angri; Raffaele Spagnuolo; Lucio Nitsch; Massimo Chiariello
Journal:  Cardiovasc Res       Date:  2005-10-01       Impact factor: 10.787

2.  Macrophage depletion alters vein graft intimal hyperplasia.

Authors:  J R Hoch; V K Stark; N van Rooijen; J L Kim; M P Nutt; T F Warner
Journal:  Surgery       Date:  1999-08       Impact factor: 3.982

3.  C-reactive protein binding to murine leukocytes requires Fc gamma receptors.

Authors:  M P Stein; C Mold; T W Du Clos
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

4.  Multifaceted role of plasminogen activator inhibitor-1 in regulating early remodeling of vein bypass grafts.

Authors:  Yan Ji; Tammy L Strawn; Elizabeth A Grunz; Meredith J Stevenson; Alexander W Lohman; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-05-12       Impact factor: 8.311

5.  CRP, IL-6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events?

Authors:  Anders Hedman; P Thomas Larsson; Mahbubul Alam; N Håkan Wallen; Rolf Nordlander; Bassem Abdel Samad
Journal:  Int J Cardiol       Date:  2006-12-01       Impact factor: 4.164

6.  Activation of inflammation and coagulation after infusion of C-reactive protein in humans.

Authors:  Radjesh J Bisoendial; John J P Kastelein; Johannes H M Levels; Jaap J Zwaginga; Bas van den Bogaard; Pieter H Reitsma; Joost C M Meijers; Daniel Hartman; Marcel Levi; Erik S G Stroes
Journal:  Circ Res       Date:  2005-03-17       Impact factor: 17.367

7.  Vitronectin inhibits the thrombotic response to arterial injury in mice.

Authors:  W P Fay; A C Parker; M N Ansari; X Zheng; D Ginsburg
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

8.  The modulation of smooth muscle cell phenotype is an early event in human aorto-coronary saphenous vein grafts.

Authors:  M M Kockx; B A Cambier; H E Bortier; G R De Meyer; P A Van Cauwelaert
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

9.  Mouse model of venous bypass graft arteriosclerosis.

Authors:  Y Zou; H Dietrich; Y Hu; B Metzler; G Wick; Q Xu
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

10.  Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent.

Authors:  Dongqi Xing; Fadi G Hage; Yiu-Fai Chen; Mark A McCrory; Wenguang Feng; Gregory A Skibinski; Erum Majid-Hassan; Suzanne Oparil; Alexander J Szalai
Journal:  Am J Pathol       Date:  2007-12-06       Impact factor: 4.307

View more
  8 in total

Review 1.  Fibrinogen Is at the Interface of Host Defense and Pathogen Virulence in Staphylococcus aureus Infection.

Authors:  Ya-Ping Ko; Matthew J Flick
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

2.  Recombinant soluble apyrase APT102 inhibits thrombosis and intimal hyperplasia in vein grafts without adversely affecting hemostasis or re-endothelialization.

Authors:  Y Ji; O Adeola; T L Strawn; S S Jeong; R Chen; W P Fay
Journal:  J Thromb Haemost       Date:  2017-02-23       Impact factor: 5.824

3.  Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome.

Authors:  Hekmat B Khoukaz; Yan Ji; Drew J Braet; Manisha Vadali; Ahmed A Abdelhamid; Cory D Emal; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-09       Impact factor: 8.311

Review 4.  Vulnerable Plaque, Characteristics, Detection, and Potential Therapies.

Authors:  Anouar Hafiane
Journal:  J Cardiovasc Dev Dis       Date:  2019-07-27

Review 5.  The Multiple Faces of C-Reactive Protein-Physiological and Pathophysiological Implications in Cardiovascular Disease.

Authors:  Magdalena Boncler; Yi Wu; Cezary Watala
Journal:  Molecules       Date:  2019-05-30       Impact factor: 4.927

Review 6.  An aberrant STAT pathway is central to COVID-19.

Authors:  Toshifumi Matsuyama; Shawn P Kubli; Steven K Yoshinaga; Klaus Pfeffer; Tak W Mak
Journal:  Cell Death Differ       Date:  2020-10-09       Impact factor: 15.828

7.  Severe bleeding following off-pump coronary artery bypass grafting: predictive factors and risk model.

Authors:  Yu Liu; Xing Wang; Zi-Ying Chen; Wen-Li Zhang; Lin Guo; Yong-Quan Sun; Hong-Zhan Cui; Ji-Qiang Bu; Jian-Hui Cai
Journal:  J Geriatr Cardiol       Date:  2021-06-28       Impact factor: 3.327

8.  Mechanical Thrombectomy of COVID-19 positive acute ischemic stroke patient: a case report and call for preparedness.

Authors:  Ossama Yassin Mansour; Amer M Malik; Italo Linfante
Journal:  BMC Neurol       Date:  2020-09-24       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.